REFRACTORY HODGKIN LYMPHOMA
Clinical trials for REFRACTORY HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo for tough hodgkin lymphoma cases
Disease control OngoingThis study tested a new treatment plan for people with Hodgkin lymphoma that returned or didn't respond to initial therapy. The approach combines an immunotherapy drug (nivolumab) with standard chemotherapy (ICE) to shrink the cancer before a stem cell transplant. The goal was to…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Can a weekly drug combo outsmart resistant lymphoma?
Disease control OngoingThis phase 2 pilot study tests whether giving brentuximab vedotin weekly, alone or with nivolumab, can help people with CD30+ lymphoma whose cancer stopped responding to the standard every-3-week dosing. The study enrolls 28 adults with relapsed or refractory Hodgkin or non-Hodgk…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Immunotherapy combo aims to stop hodgkin lymphoma relapse after transplant
Disease control OngoingThis phase 2 trial is testing whether two immunotherapy drugs, nivolumab and brentuximab vedotin, can prevent Hodgkin lymphoma from coming back after a stem cell transplant. The study includes 62 patients with high-risk Hodgkin lymphoma that had returned or not responded to prior…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New combo therapy aims to outsmart tough hodgkin lymphoma
Disease control OngoingThis early-phase pilot study is testing whether giving a PD-1 inhibitor (nivolumab or pembrolizumab) after CAR-T cell therapy can help people with relapsed or refractory classical Hodgkin lymphoma. The trial plans to enroll 10 adults whose cancer has not responded to at least thr…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for tough hodgkin lymphoma: immune drugs tested alone or together
Disease control OngoingThis study tests two immune-boosting drugs, ipilimumab and nivolumab, in people with classic Hodgkin lymphoma that has returned or not responded to prior therapy. The goal is to see if giving these drugs alone or together can shrink tumors. The trial involves 13 adults with measu…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC